1.68
+0.60%
Close of 9 Nov 2026, in THB
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About JSP Pharmaceutical Manufacturing (Thailand) PCL
Its shares trade on SET under the ticker JSP.BK. It has been listed since 2 November 2021. In the fiscal year to 31 December 2025, it reported revenue of THB 1.01bn and net income of THB 67.9m. At that date it held total assets of THB 1.46bn and shareholders' equity of THB 908.6m.
JSP Pharmaceutical Manufacturing (Thailand) Public Co. Ltd. operates the business of producing products according to customer needs, producing drugs, dietary supplements, cosmetics, herbs and dietary supplements in the form of vitamins to nourish the body. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2021-11-02. The firm manufactures and distributes products under customer’s brand name (OEM), as well as under the Company’s brand name. The firm develops, manufactures and sells conventional and traditional medicines, herbal products and dietary supplements, providing a range of services covering the manufacturer and the seller of the products under both customers’ trademark (OEM) and the seller of the products under the Company’s trademark (Own Brand). The firm develops herbal products, dietary supplements with natural extracts and plant-based protein under brand name Supap Osot, and dietary supplements such as using new raw materials or having new production process for both beauty and health under brand name EVITON. The Company’s subsidiary, Caresutic Co., Ltd., is engaged in manufacturing and distribution of dietary supplements and cosmetic products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 2 Nov 2021
- Employees
- 340
- Website
- jsppharma.com/th ↗
Leadership
Pay as last reported
- Dr. Thongchai TawichachatIndependent Chairman of the Board
- Dr. Sittichai DaengprasertPresident, Executive Director
- Ms. Jirada DaengprasertExecutive Vice President - Finance and Accounting, Executive Director, Company Secretary
- Mr. Pissanu DaengprasertExecutive Vice President - Business Development, Executive Director
- Mr. Sorasit DaengprasertExecutive Vice President - Manufacturing, Executive Director
- Mr. Tawat KitkangwanDirector
- Ms. Jintana SantipisutDirector
- Assoc. Prof. Dr. Lalita HongratanawongIndependent Director
- Ms. Sophawadee LertmanatchaiIndependent Director
- Mr. Vinit UsavakidvireeIndependent Director
- Mr. Nuttawut WibulpattanawongIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Produces custom pharmaceuticals and dietary supplements under OEM and Own Brand models
- Manufactures herbal products with natural extracts and plant-based protein under Supap Osot
- Develops new dietary supplements using innovative raw materials and production processes for EVITON
Weaknesses
- Limited to Bangkok headquarters for operations
- Relies on customer brand name for OEM business model
- Operates with only 340 employees in a growing market
Opportunities
- Expanding into new markets beyond Thailand
- Growing demand for herbal and natural health products globally
- Increasing focus on plant-based protein supplements in the health sector
Threats
- Competition from established pharmaceutical companies in Thailand
- Regulatory changes affecting herbal product approvals
- Economic downturns impacting consumer spending on supplements
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.